camrelizumab,rivoceranib
hlb bio group,jiangsu hengrui pharmaceuticals
['apatinib', 'camrelizumab', 'gyn']
camrelizumab (pd-1i) and apatinib (vegfr2i) active in recurrent #endometrialcancer 44% overall response rate 91% disease control rate important! all patients were #immunotherapy naive - so appears similar to len/pem in this space
#asco23 #gyncsm #immunoonc 
Gyn Onc at MD Anderson. She/Hers. Wife of @DrJasonWestin. Innovative clinical trials. @ASCO_JCO social media editor. Opinions=mine.
https://t.co/QLXLDKSThc